Neural crest tumor

A tumor associated with the NEURAL CREST cell lineages, including GANGLIONEUROMA and NEUROBLASTOMA.

Also Known As:

Neural crest-derived tumors

Networked: 44 relevant articles (0 outcomes, 4 trials/studies)

Disease Context: Research Results

Neoplasms: 1324753
- Neoplasms by Site: 4
  - Endocrine Gland Neoplasms: 130
    - Adrenal Gland Neoplasms: 239
      - Neural crest tumor: 44
Endocrine System Diseases: 968
- Endocrine Gland Neoplasms: 130
  - Adrenal Gland Neoplasms: 239
    - Neural crest tumor: 44
- Adrenal Gland Diseases: 24
  - Adrenal Gland Neoplasms: 239
    - Neural crest tumor: 44

Related Diseases

1.	Neuroblastoma
2.	Neoplasms (Cancer)
3.	Melanoma (Melanoma, Malignant)
4.	Disease Progression
5.	Pheochromocytoma

Experts

1.	Kitlinska, Joanna: 2 articles (01/2007 - 03/2005)
2.	Liang, Ye: 2 articles (01/2004 - 09/2002)
3.	Ahmadi Bidakhvidi, Niloefar: 1 article (12/2021)
4.	Baete, Kristof: 1 article (12/2021)
5.	Clement, Paul: 1 article (12/2021)
6.	Dekervel, Jeroen: 1 article (12/2021)
7.	Deroose, Christophe M: 1 article (12/2021)
8.	Goffin, Karolien: 1 article (12/2021)
9.	Nackaerts, Kristiaan: 1 article (12/2021)
10.	Van Cutsem, Eric: 1 article (12/2021)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Neural crest tumor:

1.	ZinostatinIBA 02/10/1998 - "Studies of the response of neural crest tumor cells to the DNA cleaving antimitotic agent, neocarzinostatin, have left unanswered the question of whether the DNA cleavage per se or the antimitotic effect is responsible for this response. " 03/01/1992 - "By using neocarzinostatin, a "pro-drug" which is activated by reduction by thiol compounds, adjunctively with 6-mercaptodopamine, a thiol-containing dopamine analogue, we have been able to enhance neocarzinostatin toxicity for cells of the neural crest tumor neuroblastoma. "
2.	Antimitotic AgentsIBA 02/10/1998 - "Studies of the response of neural crest tumor cells to the DNA cleaving antimitotic agent, neocarzinostatin, have left unanswered the question of whether the DNA cleavage per se or the antimitotic effect is responsible for this response. "
3.	Somatostatin (Somatotropin Release-Inhibiting Factor)IBA 01/01/1994 - "To investigate the presence of biologically active somatostatin (SS) receptors in neural crest-derived tumors, radioligand binding studies, cyclic AMP accumulation, intracellular calcium, and growth assays were performed in eight human neuroblastoma (NB) cell lines. "
4.	IsoenzymesIBA 01/01/1986 - "These results suggest that the I/III isozyme ratio of cAMP-PDE could be a useful marker in studies on the differentiation of neural crest-derived tumors and Schwann cells." 01/01/1986 - "Distinct isozyme patterns of cyclic nucleotide phosphodiesterase in human neuroblastoma and ganglioneuroma; a possible marker of differentiation of neural crest-derived tumors and Schwann cells."
5.	DNA (Deoxyribonucleic Acid)IBA 02/10/1998 - "Studies of the response of neural crest tumor cells to the DNA cleaving antimitotic agent, neocarzinostatin, have left unanswered the question of whether the DNA cleavage per se or the antimitotic effect is responsible for this response. "
6.	CalciumIBA 01/01/1994 - "To investigate the presence of biologically active somatostatin (SS) receptors in neural crest-derived tumors, radioligand binding studies, cyclic AMP accumulation, intracellular calcium, and growth assays were performed in eight human neuroblastoma (NB) cell lines. "
7.	Cyclic AMP (AMP, Cyclic)IBA 01/01/1994 - "To investigate the presence of biologically active somatostatin (SS) receptors in neural crest-derived tumors, radioligand binding studies, cyclic AMP accumulation, intracellular calcium, and growth assays were performed in eight human neuroblastoma (NB) cell lines. "
8.	Proteins (Proteins, Gene)FDA Link 01/01/2023 - "The TMEM127 gene encodes a transmembrane protein of poorly known function that is mutated in pheochromocytomas, neural crest-derived tumors of adrenomedullary cells. " 12/15/1991 - "In addition to NBs, lower levels of BCL2 protein were also found in a variety of other neural crest-derived tumors and tumor cell lines, including some neuroepitheliomas, Ewing's sarcomas, neurofibromas, and melanomas. " 03/01/2011 - "The clinical value of (131)I-MIBG for targeted imaging and targeted radiotherapy is limited to neural crest-derived tumors expressing human norepinephrine transporters (hNET) protein. " 01/01/2019 - "KIF1Bβ, a member of the kinesin superfamily of motor proteins, is a haploinsufficient tumor suppressor mapped to chromosome 1p36.2, which is frequently deleted in neural crest-derived tumors, including neuroblastoma and pheochromocytoma. "
9.	3-Iodobenzylguanidine (Iobenguane)IBA 03/01/2002 - "Intraoperative MIBG radionuclear scanning has been used to improve pathological foci localization and surgical accuracy in patients with neural crest derived tumors. " 01/01/1994 - "Seventy-seven I-123 MIBG scans obtained in 33 children undergoing evaluation for neural crest tumor were reviewed. " 03/01/1986 - "The authors present a case of a metastatic gastric carcinoid tumor, another neural crest tumor, concentrating I-131 MIBG, which was documented by conventional scintigraphy and SPECT in correlation with CT scans and colloid scintigrams of the liver. "
10.	Somatostatin Receptors (Somatostatin Receptor)IBA 12/28/2021 - "The only target that is currently used in clinical practice is the somatostatin receptor (SSTR), which is overexpressed on a range of tumor cells, including neuroendocrine tumors and neural-crest derived tumors. " 12/01/1994 - "Somatostatin receptors are expressed on certain neural crest-derived tumors, including pancreatic islet cell and carcinoid tumors, medullary thyroid carcinomas, pheochromocytomas, and paragangliomas. " 01/01/1999 - "The author reviewed present status and progress of endocrine nuclear medicine including thyroid, parathyroid, adrenocortical, adrenomedullary and somatostatin receptor imaging and also radionuclide therapy of Basedow's disease, metastatic foci of post-operative thyroid cancer and malignant neural crest tumor. "

Therapies and Procedures

1.	Immunotherapy 01/01/2021 - "Broadly, this study establishes a high-resolution map of the evolutionary dynamics of resistance to ICB, characterizes a de-differentiated neural-crest tumor population in melanoma immunotherapy resistance and describes site-specific differences in tumor-immune interactions via longitudinal analysis of a patient with melanoma with an unusual clinical course."
2.	Therapeutics 01/01/2017 - "Patients with neural crest-derived tumors often have poor outcomes due to frequent relapses, likely due to the continued presence of residual treatment-resistant CSCs, and therapies directed against these CSCs are likely to improve patient outcomes. " 06/03/2010 - "Our data indicate D6 as a good candidate to develop new therapies against neural crest-derived tumors." 12/02/2005 - "Thus, our findings suggest a role for GDNF signaling in promoting resistance to differentiation or cytotoxic therapy of neuroblastoma, and, preclude their use in this neural crest tumor." 01/01/1999 - "The author reviewed present status and progress of endocrine nuclear medicine including thyroid, parathyroid, adrenocortical, adrenomedullary and somatostatin receptor imaging and also radionuclide therapy of Basedow's disease, metastatic foci of post-operative thyroid cancer and malignant neural crest tumor. "
3.	Radiotherapy 03/01/2011 - "The clinical value of (131)I-MIBG for targeted imaging and targeted radiotherapy is limited to neural crest-derived tumors expressing human norepinephrine transporters (hNET) protein. "